Loading…
Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement
Purpose To assess the efficacy and safety of liposomal cytarabine in the treatment of de novo and relapsed leptomeningeal involvement in children with primary CNS tumours. Methods Data from clinical charts were entered into a database for consecutive unselected patients ( n =20) from nine Spanish ce...
Saved in:
| Published in: | Clinical & translational oncology 2012-04, Vol.14 (4), p.280-286 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c343t-6d23dc00f3b476bbb13e1d535418b5040b04a5472823a0f3addeedfbd16bbbc63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c343t-6d23dc00f3b476bbb13e1d535418b5040b04a5472823a0f3addeedfbd16bbbc63 |
| container_end_page | 286 |
| container_issue | 4 |
| container_start_page | 280 |
| container_title | Clinical & translational oncology |
| container_volume | 14 |
| creator | Navajas, Aurora Lassaletta, Álvaro Morales, Andrés López-Ibor, Blanca Sábado, Constantino Moscardó, Cristina Mateos, Elena Molina, Javier Sagaseta, María Sastre, Ana |
| description | Purpose
To assess the efficacy and safety of liposomal cytarabine in the treatment of
de novo
and relapsed leptomeningeal involvement in children with primary CNS tumours.
Methods
Data from clinical charts were entered into a database for consecutive unselected patients (
n
=20) from nine Spanish centres. Diagnosis of leptomeningeal involvement was confirmed by cytology, MRI and/or CT scan. The dose of liposomal cytarabine used varied from 20 to 50 mg, by age.
Results
There were 8 females and 12 males, mean age 7.3 years (range 8 months to 18 years). The tumours were: 10 medulloblastomas, 4 ependymomas, 3 primitive neuroectodermal tumours and 3 other tumours. Fourteen had undergone previous chemotherapy and 12 radiotherapy. Nine received concurrent chemotherapy and 2 concurrent radiotherapy. Median follow-up was 244.5 days (range 12–869). Patients received a median of 5 doses (range 1–9) of liposomal cytarabine. A neurological response (complete or partial) was seen in 11/19 (58%) and a cytological response in 7/10 (64%). Median time to neurological progression exceeded 180 days (range 12–869). Adverse effects were reported in 11/20 patients, but none was grade IV.
Discussion
Liposomal cytarabine was well tolerated and efficacious in this patient group, but prospective randomised trials are needed. |
| doi_str_mv | 10.1007/s12094-012-0796-0 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s12094_012_0796_0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22484635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-6d23dc00f3b476bbb13e1d535418b5040b04a5472823a0f3addeedfbd16bbbc63</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMotlZ_gBvJHxi9ecxrKaU-oOhCBXdDnjZlXiTTyvx7U6a6dJVw7zmHez6ErgncEoD8LhAKJU-A0ATyMkvgBM1JVpYJgzQ9Pf6BF58zdBHCFuI0I-QczSjlBc9YOkf9ylqnhBqxaDUOwpphxJ3Fteu70DWixmochBfStQa7FquNq7U3Lf52wwb33jXCj3j58oaHXdPtfJgWtemHrjGta79MzHDtvqv3Jg6GS3RmRR3M1fFdoI-H1fvyKVm_Pj4v79eJYpwNSaYp0wrAMsnzTEpJmCE6ZSknhUyBgwQuUp7TgjIRVUJrY7SVmhzEKmMLRKZc5bsQvLHV8diKQHWgV030qkivOtCrIHpuJk-_k43Rf45fXFFAJ0GIq1jNV9vYuY09_kn9AfVcfY0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement</title><source>Springer Link</source><creator>Navajas, Aurora ; Lassaletta, Álvaro ; Morales, Andrés ; López-Ibor, Blanca ; Sábado, Constantino ; Moscardó, Cristina ; Mateos, Elena ; Molina, Javier ; Sagaseta, María ; Sastre, Ana</creator><creatorcontrib>Navajas, Aurora ; Lassaletta, Álvaro ; Morales, Andrés ; López-Ibor, Blanca ; Sábado, Constantino ; Moscardó, Cristina ; Mateos, Elena ; Molina, Javier ; Sagaseta, María ; Sastre, Ana</creatorcontrib><description>Purpose
To assess the efficacy and safety of liposomal cytarabine in the treatment of
de novo
and relapsed leptomeningeal involvement in children with primary CNS tumours.
Methods
Data from clinical charts were entered into a database for consecutive unselected patients (
n
=20) from nine Spanish centres. Diagnosis of leptomeningeal involvement was confirmed by cytology, MRI and/or CT scan. The dose of liposomal cytarabine used varied from 20 to 50 mg, by age.
Results
There were 8 females and 12 males, mean age 7.3 years (range 8 months to 18 years). The tumours were: 10 medulloblastomas, 4 ependymomas, 3 primitive neuroectodermal tumours and 3 other tumours. Fourteen had undergone previous chemotherapy and 12 radiotherapy. Nine received concurrent chemotherapy and 2 concurrent radiotherapy. Median follow-up was 244.5 days (range 12–869). Patients received a median of 5 doses (range 1–9) of liposomal cytarabine. A neurological response (complete or partial) was seen in 11/19 (58%) and a cytological response in 7/10 (64%). Median time to neurological progression exceeded 180 days (range 12–869). Adverse effects were reported in 11/20 patients, but none was grade IV.
Discussion
Liposomal cytarabine was well tolerated and efficacious in this patient group, but prospective randomised trials are needed.</description><identifier>ISSN: 1699-048X</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-012-0796-0</identifier><identifier>PMID: 22484635</identifier><language>eng</language><publisher>Milan: Springer Milan</publisher><subject>Adolescent ; Brain Neoplasms - drug therapy ; Child ; Child, Preschool ; Cytarabine - therapeutic use ; Female ; Humans ; Infant ; Liposomes - therapeutic use ; Magnetic Resonance Imaging - methods ; Male ; Medicine ; Medicine & Public Health ; Meningeal Neoplasms - drug therapy ; Oncology ; Patient Safety ; Quality of Life ; Spain ; Tomography, X-Ray Computed - methods ; Treatment Outcome</subject><ispartof>Clinical & translational oncology, 2012-04, Vol.14 (4), p.280-286</ispartof><rights>Feseo 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-6d23dc00f3b476bbb13e1d535418b5040b04a5472823a0f3addeedfbd16bbbc63</citedby><cites>FETCH-LOGICAL-c343t-6d23dc00f3b476bbb13e1d535418b5040b04a5472823a0f3addeedfbd16bbbc63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22484635$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Navajas, Aurora</creatorcontrib><creatorcontrib>Lassaletta, Álvaro</creatorcontrib><creatorcontrib>Morales, Andrés</creatorcontrib><creatorcontrib>López-Ibor, Blanca</creatorcontrib><creatorcontrib>Sábado, Constantino</creatorcontrib><creatorcontrib>Moscardó, Cristina</creatorcontrib><creatorcontrib>Mateos, Elena</creatorcontrib><creatorcontrib>Molina, Javier</creatorcontrib><creatorcontrib>Sagaseta, María</creatorcontrib><creatorcontrib>Sastre, Ana</creatorcontrib><title>Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement</title><title>Clinical & translational oncology</title><addtitle>Clin Transl Oncol</addtitle><addtitle>Clin Transl Oncol</addtitle><description>Purpose
To assess the efficacy and safety of liposomal cytarabine in the treatment of
de novo
and relapsed leptomeningeal involvement in children with primary CNS tumours.
Methods
Data from clinical charts were entered into a database for consecutive unselected patients (
n
=20) from nine Spanish centres. Diagnosis of leptomeningeal involvement was confirmed by cytology, MRI and/or CT scan. The dose of liposomal cytarabine used varied from 20 to 50 mg, by age.
Results
There were 8 females and 12 males, mean age 7.3 years (range 8 months to 18 years). The tumours were: 10 medulloblastomas, 4 ependymomas, 3 primitive neuroectodermal tumours and 3 other tumours. Fourteen had undergone previous chemotherapy and 12 radiotherapy. Nine received concurrent chemotherapy and 2 concurrent radiotherapy. Median follow-up was 244.5 days (range 12–869). Patients received a median of 5 doses (range 1–9) of liposomal cytarabine. A neurological response (complete or partial) was seen in 11/19 (58%) and a cytological response in 7/10 (64%). Median time to neurological progression exceeded 180 days (range 12–869). Adverse effects were reported in 11/20 patients, but none was grade IV.
Discussion
Liposomal cytarabine was well tolerated and efficacious in this patient group, but prospective randomised trials are needed.</description><subject>Adolescent</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cytarabine - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Liposomes - therapeutic use</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meningeal Neoplasms - drug therapy</subject><subject>Oncology</subject><subject>Patient Safety</subject><subject>Quality of Life</subject><subject>Spain</subject><subject>Tomography, X-Ray Computed - methods</subject><subject>Treatment Outcome</subject><issn>1699-048X</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLAzEUhYMotlZ_gBvJHxi9ecxrKaU-oOhCBXdDnjZlXiTTyvx7U6a6dJVw7zmHez6ErgncEoD8LhAKJU-A0ATyMkvgBM1JVpYJgzQ9Pf6BF58zdBHCFuI0I-QczSjlBc9YOkf9ylqnhBqxaDUOwpphxJ3Fteu70DWixmochBfStQa7FquNq7U3Lf52wwb33jXCj3j58oaHXdPtfJgWtemHrjGta79MzHDtvqv3Jg6GS3RmRR3M1fFdoI-H1fvyKVm_Pj4v79eJYpwNSaYp0wrAMsnzTEpJmCE6ZSknhUyBgwQuUp7TgjIRVUJrY7SVmhzEKmMLRKZc5bsQvLHV8diKQHWgV030qkivOtCrIHpuJk-_k43Rf45fXFFAJ0GIq1jNV9vYuY09_kn9AfVcfY0</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Navajas, Aurora</creator><creator>Lassaletta, Álvaro</creator><creator>Morales, Andrés</creator><creator>López-Ibor, Blanca</creator><creator>Sábado, Constantino</creator><creator>Moscardó, Cristina</creator><creator>Mateos, Elena</creator><creator>Molina, Javier</creator><creator>Sagaseta, María</creator><creator>Sastre, Ana</creator><general>Springer Milan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20120401</creationdate><title>Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement</title><author>Navajas, Aurora ; Lassaletta, Álvaro ; Morales, Andrés ; López-Ibor, Blanca ; Sábado, Constantino ; Moscardó, Cristina ; Mateos, Elena ; Molina, Javier ; Sagaseta, María ; Sastre, Ana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-6d23dc00f3b476bbb13e1d535418b5040b04a5472823a0f3addeedfbd16bbbc63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cytarabine - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Liposomes - therapeutic use</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meningeal Neoplasms - drug therapy</topic><topic>Oncology</topic><topic>Patient Safety</topic><topic>Quality of Life</topic><topic>Spain</topic><topic>Tomography, X-Ray Computed - methods</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Navajas, Aurora</creatorcontrib><creatorcontrib>Lassaletta, Álvaro</creatorcontrib><creatorcontrib>Morales, Andrés</creatorcontrib><creatorcontrib>López-Ibor, Blanca</creatorcontrib><creatorcontrib>Sábado, Constantino</creatorcontrib><creatorcontrib>Moscardó, Cristina</creatorcontrib><creatorcontrib>Mateos, Elena</creatorcontrib><creatorcontrib>Molina, Javier</creatorcontrib><creatorcontrib>Sagaseta, María</creatorcontrib><creatorcontrib>Sastre, Ana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical & translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Navajas, Aurora</au><au>Lassaletta, Álvaro</au><au>Morales, Andrés</au><au>López-Ibor, Blanca</au><au>Sábado, Constantino</au><au>Moscardó, Cristina</au><au>Mateos, Elena</au><au>Molina, Javier</au><au>Sagaseta, María</au><au>Sastre, Ana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement</atitle><jtitle>Clinical & translational oncology</jtitle><stitle>Clin Transl Oncol</stitle><addtitle>Clin Transl Oncol</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>14</volume><issue>4</issue><spage>280</spage><epage>286</epage><pages>280-286</pages><issn>1699-048X</issn><eissn>1699-3055</eissn><abstract>Purpose
To assess the efficacy and safety of liposomal cytarabine in the treatment of
de novo
and relapsed leptomeningeal involvement in children with primary CNS tumours.
Methods
Data from clinical charts were entered into a database for consecutive unselected patients (
n
=20) from nine Spanish centres. Diagnosis of leptomeningeal involvement was confirmed by cytology, MRI and/or CT scan. The dose of liposomal cytarabine used varied from 20 to 50 mg, by age.
Results
There were 8 females and 12 males, mean age 7.3 years (range 8 months to 18 years). The tumours were: 10 medulloblastomas, 4 ependymomas, 3 primitive neuroectodermal tumours and 3 other tumours. Fourteen had undergone previous chemotherapy and 12 radiotherapy. Nine received concurrent chemotherapy and 2 concurrent radiotherapy. Median follow-up was 244.5 days (range 12–869). Patients received a median of 5 doses (range 1–9) of liposomal cytarabine. A neurological response (complete or partial) was seen in 11/19 (58%) and a cytological response in 7/10 (64%). Median time to neurological progression exceeded 180 days (range 12–869). Adverse effects were reported in 11/20 patients, but none was grade IV.
Discussion
Liposomal cytarabine was well tolerated and efficacious in this patient group, but prospective randomised trials are needed.</abstract><cop>Milan</cop><pub>Springer Milan</pub><pmid>22484635</pmid><doi>10.1007/s12094-012-0796-0</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-048X |
| ispartof | Clinical & translational oncology, 2012-04, Vol.14 (4), p.280-286 |
| issn | 1699-048X 1699-3055 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_s12094_012_0796_0 |
| source | Springer Link |
| subjects | Adolescent Brain Neoplasms - drug therapy Child Child, Preschool Cytarabine - therapeutic use Female Humans Infant Liposomes - therapeutic use Magnetic Resonance Imaging - methods Male Medicine Medicine & Public Health Meningeal Neoplasms - drug therapy Oncology Patient Safety Quality of Life Spain Tomography, X-Ray Computed - methods Treatment Outcome |
| title | Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T06%3A41%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20liposomal%20cytarabine%20in%20children%20with%20primary%20CNS%20tumours%20with%20leptomeningeal%20involvement&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Navajas,%20Aurora&rft.date=2012-04-01&rft.volume=14&rft.issue=4&rft.spage=280&rft.epage=286&rft.pages=280-286&rft.issn=1699-048X&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-012-0796-0&rft_dat=%3Cpubmed_cross%3E22484635%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c343t-6d23dc00f3b476bbb13e1d535418b5040b04a5472823a0f3addeedfbd16bbbc63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22484635&rfr_iscdi=true |